✦ LIBER ✦

Pramipexole augments benefits of atypical antipsychotics in patients with schizophrenia or schizoaffective disorder

✍ Scribed by J.P. Kelleher; F. Centorrino; N.A. Huxley; J. Hennen; M. Eakin; J. Kidwell; S. Egli; J.M. Berry; K.V. Fogarty; V.H. Fellman; R.J. Baldessarini

Book ID: 119555585
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 127 KB
Volume: 60
Category: Article
ISSN: 0920-9964
DOI: 10.1016/s0920-9964(03)80479-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of therapy with atypical antipsyc

Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders

✍ L. N. Gorobets 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 250 KB

Combination of “atypical” antipsychotic

Combination of “atypical” antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder

✍ Vladimir Lerner; Igor Libov; Moshe Kotler; Rael D Strous 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 213 KB

Responses to antipsychotic therapy among

Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms

✍ Virginia L. Stauffer; Guochen Song; Bruce J. Kinon; Haya Ascher-Svanum; Lei Chen 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 568 KB

A randomized controlled trial of allopur

A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder

✍ Mark Weiser; Ari A. Gershon; Katya Rubinstein; Camelia Petcu; Maria Ladea; Dorin 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 156 KB

Predictors of antipsychotic treatment re

Predictors of antipsychotic treatment response in patients with first episode schizophrenia, schizoaffective, and schizophreniform disorders

✍ D.O. Perkins; J.A. Lieberman; H. Gu; M. Tohen; J. McEvoy; A. Green; R. Zipursky; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 127 KB

PMH25 CLINICAL OUTCOMES AND ECONOMIC COS

PMH25 CLINICAL OUTCOMES AND ECONOMIC COSTS OF SECOND-GENERATION ANTIPSYCHOTICS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDERS

✍ A. Berger; S. Kushkuley; K. Sanders; J. Alvir; G. Oster 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB